SCHEMBL25252018

SCHEMBL25252018

CCOC(=O)C1(c2ccccn2)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.47
TSHR P16473 2/20 0.46
ALOX15 P16050 1/20 0.46
ATM Q13315 1/20 0.46
OPRD1 P41143 7/20 0.46
OPRK1 P41145 6/20 0.46
OPRM1 P35372 6/20 0.46
SLC22A1 O15245 1/20 0.46
SLC6A4 P31645 1/20 0.46
ADRA1A P35348 1/20 0.46
KCNH2 Q12809 1/20 0.46
POLB P06746 1/20 0.44
NOS2 P35228 1/20 0.44
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GRM5 P41594 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2589377 0.85 GPR119 (0.52) GPR119TSHRALOX15ATMOPRD1
SCHEMBL8347288 0.85 GPR119 (0.52) GPR119TSHRALOX15ATMOPRD1
SCHEMBL22495695 0.85 POLB (0.47) GPR119TSHRALOX15ATMOPRD1
SCHEMBL30018031 0.84 GPR119 (0.51) GPR119TSHRALOX15ATMOPRD1
SCHEMBL8353022 0.84 GPR119 (0.51) GPR119TSHRALOX15ATMOPRD1
SCHEMBL28490994 0.83 GPR119 (0.42) GPR119OPRD1OPRK1POLBNOS2
Potassium Ion SCHEMBL2590846 0.83 GPR119 (0.50) GPR119TSHRALOX15ATMOPRD1
SCHEMBL3091664 0.83 OPRM1 (0.47) TSHRALOX15ATMOPRD1OPRK1
SCHEMBL14239619 0.83 TSHR (0.42) GPR119TSHRALOX15ATMOPRD1
SCHEMBL16130068 0.83 OPRM1 (0.67) TSHRALOX15ATMOPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2023-07-27 US disclosed
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2023-07-27 US disclosed
EP-4192458-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 Therapeutics, Inc. (US) 2023-06-14 EP disclosed
WO-2022032026-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET RET, HRAS, RBX1 GPR119 3419/4885TSHR 1709/4885ALOX15 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.